Corriente Advisors’s Viracta Therapeutics VIRX Stock Holding History
Bought
Maintained
Sold
Other funds holding VIRX
BBA
Corriente Advisors's VIRX Position: Q2 2020 in Review
Corriente Advisors sold out of Viracta Therapeutics (VIRX) in Q2 2020, closing a stake of 86,334 shares — an estimated $1.25M sold.
Corriente Advisors first reported a position in VIRX in Q1 2020 and held it in 1 quarter. The position peaked at $1.25M in Q1 2020. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.
- Corriente Advisors reported no remaining Viracta Therapeutics position as of Q2 2020 after selling out during the quarter.
- Corriente Advisors sold 86,334 Viracta Therapeutics shares in Q2 2020, an estimated $1.25M.
- Corriente Advisors first reported a position in Viracta Therapeutics in Q1 2020 and held it in 1 quarter.
- Corriente Advisors's Viracta Therapeutics position peaked at $1.25M in Q1 2020.
- 41 funds tracked by Wall St. Rank held Viracta Therapeutics as of Q2 2020.
Based on Corriente Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.